Research reportOlanzapine monotherapy and olanzapine combination therapy in the treatment of mania: 12-week results from the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM) observational study☆
Introduction
Over the last 5 years, our knowledge on the treatment of mania has outstandingly increased due to the data from randomized clinical trials: Atypical antipsychotics such as olanzapine, risperidone, quetiapine, ziprasidone, and aripiprazole have been compared with placebo and with active compounds (haloperidol, lithium, and divalproex), and the evidence base for the use of all these compounds has been considerably enriched (Vieta and Goikolea, 2005). The knowledge of the actual use of antimanic agents in routine clinical conditions is quite limited, however, and large observational studies are rare (Vieta et al., 2001). Observational studies are more likely to be challenged for their internal validity than randomized clinical trials, but provide relevant data about the actual use of therapies either as monotherapy or combination therapy in “real world” patients (that is, without excluding comorbidities or suicide risk, including flexible and broader dose ranges, and across all ranges of illness severity).
Olanzapine has been tested in randomized designs in mania and compared with placebo (Tohen et al., 1999, Tohen et al., 2000), haloperidol (Tohen et al., 2002b, Tohen et al., 2003), divalproex (Zajecka et al., 2002, Tohen et al., 2002a), and risperidone (Perlis et al., 2006). Olanzapine cotherapy with lithium or divalproex was also compared with lithium and divalproex alone in one trial (Tohen et al., 2002b, 2004). Olanzapine proved to be effective for the acute treatment of mania and beyond (Vieta, 2004). Hence, a good number of studies provide an excellent evidence base for the use of olanzapine (both in mono- and combination therapy) as an antimanic agent, but less is known about the factors that drive the choice of olanzapine as monotherapy or combination, its dosages in routine clinical practice, and the patterns of use across different countries.
To close this gap, we conducted the EMBLEM (European Mania in Bipolar Longitudinal Evaluation of Medication), one of the largest observational studies ever conducted in patients suffering form bipolar mania. The objectives of the EMBLEM were to learn about the clinical and functional outcomes and patterns of use of antimanic therapy including olanzapine (both in monotherapy and in combination therapy) across several European countries.
Section snippets
Study objective
EMBLEM is a large, prospective, multicentre, observational study on the outcomes of patients after an episode of mania. From December 2002 to June 2004, 530 investigators enrolled patients from 14 European countries (Belgium, Denmark, Finland, France, Germany, Greece, Ireland, Italy, The Netherlands, Norway, Portugal, Spain, Switzerland, and the UK). Observations were completed with 5 further data collections as part of the acute phase, which lasted for 12 weeks, until October 2004. Further
Baseline patient characteristics
Of 3681 manic patients enrolled in the study, 2004 (54.4%) received olanzapine for the treatment of their manic or mixed symptoms. Of the 2004 patients, 673 (33.6%) were treated with olanzapine as antimanic monotherapy, and 1331 (66.4%) received olanzapine in combination with other antipsychotics, anticonvulsants, and/or lithium.
The demographic characteristics of the sample are shown in Table 1. Of the sample studied, 35% of patients were inpatients, and alcohol and cannabis abuse were present
Discussion
The acute-phase results of this large, multicentre, observational study that investigated the use of olanzapine (as either monotherapy or combination therapy) in European patients with mania showed significant within-group improvements from baseline to endpoint in all of the following scales: CGI-BP overall, mania, and depression; YMRS; and HAMD-5. Moreover, the rates of work impairment significantly decreased in both treatment groups at endpoint.
Although results of observational studies should
Acknowledgements
The authors of this report would like to thank the EMBLEM (European Mania in Bipolar Longitudinal Evaluation of Medication) Advisory Board for their participation in the design and conduct of the study: Prof Bernard Sabbe (Belgium); Dr Jens Knud Larsen (Denmark); Prof Hannu Koponen (Finland); Dr Isabelle Gasquet and Prof Jean Michel Azorin (France); Dr Heinz Grunze (Germany); Prof Giovanni Battista Cassano (Italy); Prof Willem Nolen and Prof Jim van Os (Netherlands); Dr Trond Aarre (Norway);
References (18)
- et al.
Principal components of mania
J. Affect. Disord.
(2003) - et al.
Modification of the Clinical Global Impressions (CGI) scale for use in bipolar illness (BP): the CGI-BP
Psychiatry Res.
(1997) - et al.
Efficacy of olanzapine combined with valproate or lithium in the treatment of dysphoric mania
Br. J. Psychiatry
(2004) - et al.
Olanzapine versus placebo in acute mania: treatment responses in subgroups
J. Clin. Psychopharmacol.
(2003) - et al.
Comparisons of psychotropic drug prescribing patterns in acute psychiatric wards across Europe
Eur. J. Clin. Pharmacol.
(2004) - et al.
Bipolar disorder in Spain: functional status and resource use on the basis of the Spanish sample of the observational, Pan European EMBLEM study
Vertex
(2007) - et al.
Olanzapine versus risperidone in the treatment of manic or mixed states in bipolar I disorder: a randomized, double-blind trial
J. Clin. Psychiatry
(2006) - et al.
Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group
Am. J. Psychiatry.
(1999) - et al.
Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The olanzipine HGGW study group
Arch. Gen. Psychiatry
(2000)
Cited by (49)
Mood stabilizers and antipsychotics during breastfeeding: Focus on bipolar disorder
2016, European NeuropsychopharmacologyCitation Excerpt :The evidence on the safety of the treatment with LTG during breastfeeding derives from one naturalistic, three open studies and various case reports and series, reporting high variability in infants’ plasma concentrations and in M/P ratios but no serious adverse effects or cognitive and development alterations (Meador et al., 2010, 2014; Veiby et al., 2013; Tomson et al., 1997; Rambeck et al., 1997; Ohman et al., 2000; Liporace et al., 2004; Gentile, 2005; Page-Sharp et al., 2006; Newport et al., 2008; Fotopoulou et al., 2009), with the exception of elevated platelet counts in 7 out of 8 children without clinical consequences (Newport et al., 2008), a case of mild apnea and cyanosis with therapeutic values of LTG of 4.9 μg/ml in infant׳s serum (Nordmo et al., 2009) and another case of an intermittently occurring skin rash of little clinical relevance (Wakil et al., 2009) (Table 1). During the last years, an increased number of studies have supported the use of antipsychotics (APs)- especially second generation APs- as a valid therapeutic alternative for the treatment of BD, both as monotherapy and as adjunctive treatment to traditional mood stabilizers (Vieta et al., 2008a, 2008b, 2010, 2011; Yildiz et al., 2011) (Table 2). From the available studies, treatment with most APs does not preclude breastfeeding.
Status quo: What do observational studies tell us?
2015, Psiquiatria BiologicaMixed states with predominant manic or depressive symptoms: Baseline characteristics and 24-month outcomes of the EMBLEM cohort
2013, Journal of Affective DisordersCitation Excerpt :A first step to confirm a relevant heterogeneity within mixed states would be to identify different factors associated with those states. The European mania in bipolar longitudinal evaluation of medication (EMBLEM) study was a prospective, observational study aimed at evaluating long- and short-term outcomes of patients presenting a manic or a mixed episode and at assessing the clinical and functional outcomes (Goetz et al., 2007; Haro et al., 2006; Montoya et al., 2007; Schuepbach et al., 2006; Vieta et al., 2008). The aim of this analysis is to describe and compare the baseline characteristics and 24-month clinical course of MSDS and MSMS in this cohort.
New treatment guidelines for acute bipolar mania: A critical review
2012, Journal of Affective DisordersEffectiveness of olanzapine monotherapy and olanzapine combination treatment in the long term following acute mania - Results of a two year observational study in bipolar disorder (EMBLEM)
2011, Journal of Affective DisordersCitation Excerpt :The increased incidence of akathisia and tremor may be related to the use of conventional antipsychotics in combination with olanzapine. Patients treated with olanzapine (both as monotherapy and in combination therapy) experienced weight gain during the maintenance phase as has been previously reported (Torrent et al, 2008), which was significantly greater in the monotherapy group, and was additional to the weight gain that occurred during the 12-week acute treatment phase (Vieta et al., 2008). Although, the mean dose of olanzapine was significantly higher in the combination group compared with the monotherapy group, the actual difference in dosage was small.
- ☆
Role of funding source: The EMBLEM study is funded by Eli Lilly and Company Limited, Windlesham, Surrey, UK. Contributors: All the authors have been sufficiently involved in the study submitted. Conflict of interest: Eduard Vieta, has acted as a consultant, received grants, or been hired as a speaker by the following companies: Almirall, AstraZeneca, Bial, Bristol-Myers-Squibb, Eli Lilly, GlaxoSmithKline, Janssen-Cilag, Lundbeck, Merck Sharp & Dohme, Novartis, Organon, Otsuka, Pfizer, Sanofi Aventis, Servier, UCB. He has acted as consultant and has received grants from the Spanish Ministry of Health, Instituto de Salud Carlos III, RETICS RD06/0011 (REM-TAP) and from the Stanley Medical Research Institute. Iris Goetz, Catherine Reed, and Mauricio Tohen are Eli Lilly and Company employees. Francesco Panicali and Merce Comes have no conflict of interest.